Cellectis (Cellectis) Debt-to-Asset : 0.40 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Cellectis Debt-to-Asset?

Cellectis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $13.14 Mil. Cellectis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $70.81 Mil. Cellectis's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $209.70 Mil. Cellectis's debt to asset for the quarter that ended in Sep. 2023 was 0.40.

Cellectis Debt-to-Asset Historical Data

The historical data trend for Cellectis's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Debt-to-Asset Chart

Cellectis Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.10

0.23

0.26

0.29

Cellectis Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Asset	Get a 7-Day Free Trial															0.35	0.29	0.30	0.39	0.40

Competitive Comparison of Cellectis's Debt-to-Asset

For the Biotechnology subindustry, Cellectis's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellectis's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cellectis's Debt-to-Asset falls into.

Cellectis Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cellectis's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(12.844	+	62.927)	/	261.216
	=	0.29

Cellectis's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(13.137	+	70.813)	/	209.7
	=	0.40

Cellectis (NAS:CLLS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Cellectis Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cellectis's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis (Cellectis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

CMVLF:USA 0WA2:UK ALCLS:France ZVAA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.